Table 1 Demographic characteristics of patients for HSDS analysisa
| Variable | ANSWER Program® | NordiNet® IOS | All |
|---|---|---|---|
| Age at GH start, years | n = 71 | n = 58 | n = 129 |
| Mean (SD) | 4.98 (4.73) | 3.74 (4.18) | 4.42 (4.51) |
| Median (range) | 3.06 (0.15–17.56) | 1.80 (0.39–15.81) | 2.15 (0.15–17.56) |
| Female, % | 59% | 40% | 50% |
| Baseline BA/CA ratiob |
n = 15 1.04 (0.17) |
n = 13 0.79 (0.31) |
n = 28 0.92 (0.27) |
| Final BA/CA ratiob |
n = 32 1.04 (0.18) |
n = 27 0.88 (0.17) |
n = 59 0.97 (0.19) |
| GH baseline dose, mg/kg/d |
n = 71 0.03 (0.01) |
n = 58 0.03 (0.01) |
n = 129 0.03 (0.01) |
| GH final dose, mg/kg/db |
n = 61 0.03 (0.01) |
n = 55 0.03 (0.01) |
n = 116 0.03 (0.01) |
| IGF-1 SDSb |
n = 31 −0.58 (1.79) |
n = 34 − 0.84 (1.72) |
n = 65 − 0.71 (1.75) |
| Baseline height, cm |
n = 71 95.00 (33.47) |
n = 58 88.75 (27.61) |
n = 129 92.19 (31.01) |
| Baseline weight, kg |
n = 71 24.65 (24.22) |
n = 58 17.47 (18.56) |
n = 129 21.42 (22.07) |
| Last recorded height, cm |
n = 71 124.2 (31.14) |
n = 58 122.1 (27.65) |
n = 129 123.2 (29.52) |
| Mid-parental target height, cmb |
n = 60 164.1 (25.33) |
n = 38 174.5 (8.37) |
n = 98 168.1 (21.04) |
| Baseline HSDS |
n = 71 −1.17 (1.40) |
n = 58 −1.94 (1.52) |
n = 129 − 1.52 (1.50) |
| Final HSDS |
n = 71 −0.28 (1.27) |
n = 58 − 0.72 (1.11) |
n = 129 − 0.48 (1.22) |
| Years of follow-up | n = 71 | n = 58 | n = 129 |
| Mean (SD) | 2.39 (1.33) | 2.59 (1.29) | 2.48 (1.31) |
| Median (range) | 2.57 (0.06, 3.93) | 3.10 (0.16, 3.98) | 2.63 (0.06, 3.98) |